Berkeley, CA, United States
Berkeley, CA, United States

Time filter

Source Type

News Article | November 14, 2016
Site: www.reuters.com

(Reuters) - The U.S. Food and Drug Administration rejected Dynavax Technologies Corp's hepatitis B vaccine for the second time in three years, casting doubts on the drug developer's ability to bring its main drug to the market on its own.


— The report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Non-Hodgkin Lymphoma - Pipeline Review, H2 2016 addition with 323 market data tables and 17 figures, spread across 1630 pages is available at http://www.reportsnreports.com/reports/781973-non-hodgkin-lymphoma-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Companies Discussed /Mentioned in this Research: 3SBio Inc, 4SC AG, AB Science SA, AbbVie Inc, Acetylon Pharmaceuticals Inc, Actelion Ltd, Actinium Pharmaceuticals Inc, BioAtla LLC, BioLineRx Ltd, Bionovis SA, Biothera Pharmaceutical Inc, bluebird bio Inc, Boehringer Ingelheim GmbH, Cellectar Biosciences Inc, Clevexel Pharma SA, Dynavax Technologies Corp, ImmunoGen Inc, Immunovaccine Inc, Japan Tobacco Inc, Mabion SA, Merck KGaA, SialoTec GmbH, Trillium Therapeutics Inc, United BioPharma Inc, Unum Therapeutics Inc, Verastem Inc, Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=781973 premium report price at US$2000 for a single user PDF license). Scope • The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma • The report reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects • The report assesses Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type • The report summarizes all the dormant and discontinued pipeline projects • The report reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma Reasons to buy • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma • Identify potential new clients or partners in the target demographic • Develop strategic initiatives by understanding the focus areas of leading companies • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics • Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline For more information, please visit http://www.reportsnreports.com/reports/781973-non-hodgkin-lymphoma-pipeline-review-h2-2016.html


MarketStudyReport.com adds “Global Travel Vaccines Market 2016-2020” new report to its research database. The report spread across 60 pages with table and figures in it. The Report analysts forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020. About Travel Vaccines As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these known infectious diseases, the travelers are advised to follow the region-specific immunization plan. The market is growing because various government bodies have mandated the immunization of travelers visiting the infectious-prone areas with various types of vaccines. This, in turn, prevents the spread of infection and averts any chances of epidemic outbreaks. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-travel-vaccines-market-2016-2020/ The report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The market is divided into the following segments based on geography:  Americas APAC EMEA The Report Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors  GlaxoSmithKline Merck Pfizer Sanofi Other prominent vendors  Abbott AstraZeneca Bavarian Nordic Baxter Beijing Minhai Biotechnology Bharat Biotech Bharat Immunologicals and Biologicals Bio-Med Seqirus CSL Crucell CSL Dynavax Technologies Emergent BioSolutions GlycoVaxyn GreenSignal Bio Pharma Hualan Biological Engineering Imunoloski Zavod Indian Immunologicals Janssen Pharmaceuticals JN International Medical Kaketsuken LG Life Sciences Lupin Mitsubishi Tanabe Pharma Novavax Nuron Biotech Panacea Biotec Pfizer Protein Sciences Roche SK Chemicals Serum Institute of India Shenzhen Kangtai Biological Products Sinovac Biotech Takeda Pharmaceutical Vacunas Finlay Valeant Pharmaceuticals Valneva, Zydus Cadila Market driver  Growing demand among travelers  For a full, detailed list, view our report  Market challenge  Requires specific storage and distribution system  For a full, detailed list, view our report  Market trend  Combination vaccines For a full, detailed list, view our report  Key questions answered in this report  What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | October 28, 2016
Site: www.prweb.com

The Hepatitis B Foundation today announced the launch of a campaign to more effectively share with the public the impact that living with hepatitis B has on individual lives and to put a human face on this serious liver disease. The goal of the Hepatitis B Foundation Patient Storytelling Program is to use the real voices of every-day people living with or affected by hepatitis B to create a national resource of personal stories. The program aims to raise awareness of the disease, decrease the associated stigma and discrimination, and promote the importance of increased testing and referral to care for hepatitis B. Participants will be recruited from across the country and invited to attend a four-day digital storytelling workshop where they will develop their stories as a short video and then complete training to share their story and videos in their own communities and at national advocacy events. The announcement of the new nationwide initiative comes as the United States observes Liver Cancer Awareness Month during October. Chronic infection with the hepatitis B virus is the leading cause of liver cancer worldwide, and liver cancer is the second leading cause of all cancer deaths globally. In the U.S., liver cancer is one of three cancers that is increasing in incidence while the rates of most other types of cancer are declining or stabilizing. “What better way to acknowledge the burden of the world’s most common, serious liver infection than by creating a program to help people affected by hepatitis B share their stories,” said Joan Block, RN, BSN, executive director and co-founder of the Hepatitis B Foundation. “Our goal is to make hepatitis B an urgent public health priority, and to increase awareness about the enormous impact of this disease on individual lives through personal storytelling.” With educational grants from Arbutus Biopharma, focused on developing new hepatitis B therapeutics, and Dynavax Technologies, focused on developing a new adult hepatitis B vaccine, the Hepatitis B Foundation will partner with StoryCenter, a nonprofit organization that started the global digital storytelling movement. The Hepatitis B Foundation Patient Storytelling Campaign will be completed and ready to share with the public by May 2017, to mark Hepatitis Awareness Month. If you have been impacted by hepatitis B, contact the Hepatitis B Foundation at info(at)hepb(dot)org or by calling 215-489-4900 to find out how you can share your story. About the Hepatitis B Foundation: The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to http://www.hepb.org, read our blog at http://www.hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at http://www.facebook.com/hepbfoundation or call 215-489-4900.


News Article | November 23, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Biodefense Market Size By Product (Anthrax, Small Pox, Botulism, Radiation/ Nuclear), Industry Analysis Report, Regional Outlook (U.S., Canada, U.K, Germany, China, Japan, Mexico, Brazil, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016-2024” new report to its research database. The report spread across 82 pages with table and figures in it. Global Biodefense Market size contribution was $9.8 billion for 2015 with CAGR of 6.91% predicted to be registered for forecast timeline. Rising bioterrorism threat and government support against bioterrorism are main aspects that are predicted to promote industry expansion in future. Many government legislations like project bioshield offers nations with counter measures against chemical, radiological, nuclear and biological attack. U.S. Biodefense Market Size, by Product, 2012 ? 2024 (USD Million) Project bioshield assures accessibility of next generation medical countermeasures against smallpox and anthrax agents. Main goal of the project is creating funding authority to build next generation counter measures, make innovative research & development programs and create a body like FDA (Food & Drug Administration) that can effectively use treatments in case of emergencies. All these factors are predicted to drive global biodefense industry trends.Furthermore, enhanced alertness displayed by public health organizations by investing in biodefense technology, skilled persons and materials along with heavy government support as well as funding from private & public sectors are predicted to contribute towards global biodefense market growth. Product Trends Global biodefense industry is segmented into products like botulism, anthrax, nuclear/radiation and small pox. Anthrax product segment contributed about 31.6% to global biodefense market share for 2015 and is projected to surpass revenue of $4.21 billion by end of forecast timeframe. The reason for segment growth can be credited to the fact that bacillus anthracis is identified as greatest priority in biodefense study and positioned among 9 agents in A class according to CDC (Centers for Disease Control and Prevention) classification. Further, government projects like BioShield, BARDA (Biomedical Advanced Research and Development Authority) and Joint Program Executive Office-Chemical and Biological Defenses offer large funding and vaccine doses against anthrax. All these factors are predicted to propel segment growth in future. Radiation segment is predicted to record higher CAGR during forecast timeline. Rapid increase in research & development activities owing to outbreak of Ebola virus and possible use of the virus as bio weapon is projected to promote segment growth. Regional Trends Global biodefense market is segmented into geographical locations like APAC, Latin America, Europe, MEA and North America. North America biodefense industry dominated the global industry by accounting for highest regional revenue share for 2015. It contributed about $8.91 billion in terms of revenue for this year. U.S. biodefense market share led the regional industry for 2015 in terms of revenue. The growth of the industry in U.S. cane be credited to factors like large scale funding for biodefense activities and government support. Europe biodefense market is anticipated to register maximum CAGR of 11.41% during forecast timeline. UK?s ministry of defense contributed highest regional industry share for 2012 by providing funds worth $75.67 million for defense & civilian research. Competitive Trends Key industry participants profiled in the report include Emergent Biosolutions, SIGA Technologies, Ichor Medical Systems Incorporation, PharmaAthene, Cleveland BioLabs Incorporation, Achaogen, Alnylam Pharmaceuticals, Xoma Corporation, Dynavax Technologies Incorporation, Elusys Therapeutics, DynPort Vaccine Company LLC, Bavarian Nordic and Nanotherapeutics Incorporation. To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


BERKELEY, CA--(Marketwired - December 05, 2016) - Dynavax Technologies Corporation ( : DVAX) today announced clinical data from an ongoing Phase 1/2, two-part clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lymphoma. The combination of intratumoral SD-101 and low-dose irradiation resulted in tumor regression in untreated tumor sites as well as in the treated tumors. Treatment was well-tolerated and changes in T cell populations consistent with stimulation of anti-tumor immunity were observed in the treated lesions. These data were presented in a poster session on Sunday at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California. Data from the dose escalation and expansion phase of the study were reported from 28 evaluable patients. None of the patients had received prior treatment for their low-grade lymphoma. The primary endpoints of the trial are maximum tolerated dose (MTD) and evaluation of the safety of intratumoral SD-101 in combination with low dose radiotherapy. In addition, the trial is evaluating anti-tumor activity, pharmacodynamics, and duration of response. Doses ranged from 1 mg to 8 mg per injection in successive cohorts. "The clinical data emerging from our SD-101 program continues to be encouraging. We look forward to providing updates from our ongoing clinical trials," stated Eddie Gray, chief executive officer of Dynavax Technologies. "We will discuss this program and our oncology pipeline in our cancer R&D Day which will be webcast live on December 9th at 8:30 a.m. EST." SD-101 is Dynavax's proprietary, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. SD-101 is being studied for its multiple anti-tumor activities in innate immune cells and activation of plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its safety and activity. For information about SD-101 trials that are currently recruiting patients, please visit www.clinicaltrials.gov. Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com. This press release contains "forward-looking" statements, including expectations for the conduct and timing of clinical trials of SD-101. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether we can timely provide adequate clinical supplies, initiate one or more studies, enroll a sufficient number of subjects and ultimately complete any study, and whether or not Dynavax and parties with whom we are collaborating may reach any future agreement on further studies or a more extensive collaboration beyond the clinical trials contemplated under the existing agreements, as well as other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.


— Follicular Lymphoma Pipeline Market Companies Involved in Therapeutics Development are AbbVie Inc, Affimed GmbH, Amgen Inc, Asana BioSciences LLC, Bayer AG, BeiGene Ltd, Bio-Path Holdings Inc, Biocon Ltd, Biogen Inc, Biogenomics Limited, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Celltrion Inc, Cellular Biomedicine Group Inc, Coherus BioSciences Inc, Constellation Pharmaceuticals Inc, CSPC Pharmaceutical Group Limited, CTI BioPharma Corp, Curis Inc, Dynavax Technologies Corp, Eisai Co Ltd, EpiZyme Inc, F. Hoffmann-La Roche Ltd, Genentech Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Hutchison MediPharma Ltd, Immune Design Corp, ImmunoGen Inc, Immunomedics Inc, Johnson & Johnson, Juno Therapeutics Inc, Karyopharm Therapeutics Inc, Kite Pharma Inc, MedImmune LLC, Medivation Inc, MEI Pharma Inc, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc, MorphoSys AG, Nordic Nanovector ASA, Novartis AG, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharmacyclics Inc, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Sandoz International GmbH, Seattle Genetics Inc, Takeda Pharmaceutical Company Ltd, TG Therapeutics Inc and Verastem Inc. Follicular lymphoma is a common type of non-Hodgkin Lymphoma (NHL). It is a slow-growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an "indolent" or "low-grade" lymphoma for its slow nature. Follicular lymphoma mainly affects older adults. Enlargement of lymph nodes is a common symptom. Fever, weight loss, sweating and fatigue are other symptoms of lymphoma. There are different types of treatment for patients with follicular lymphoma such as surgery, radiation therapy, and chemotherapy. This research provides comprehensive information on the therapeutics under development for Follicular Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774097 The Follicular Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 10, 46, 29, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively. Follicular Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Follicular Lymphoma (Oncology). • The pipeline guide reviews pipeline therapeutics for Follicular Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Follicular Lymphoma (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Follicular Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Follicular Lymphoma (Oncology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Follicular Lymphoma (Oncology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Follicular Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774097-follicular-lymphoma-pipeline-review-h2-2016.html


News Article | December 28, 2016
Site: marketersmedia.com

The analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020. According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose. Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. For more information or any query mail at sales@wiseguyreports.com The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines. The market is divided into the following segments based on geography: • Americas • APAC • Europe The report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Other prominent vendors • Abbott • AstraZeneca • Bavarian Nordic • Baxter • Bharat Biotech • Bharat Immunologicals and Biologicals • bioCSL • Bio Med • Crucell • Dynavax Technologies • Indian Immunologicals • Janssen Pharmaceuticals • Kaketsuken • LG Life Sciences • Mitsubishi Tanabe Pharma • Lupin • Nuron • Novartis • Protein Sciences Corporation • Panacea Biotec • Roche • Serum Institute of India • Shenzhen Kangtai Biological Products • Sinovac Biotech • S K Chemicals • Takeda Pharmaceutical • Valeant Pharmaceuticals • Zydus Cadila Market driver • Growing awareness about vaccination and immunization programs • For a full, detailed list, view our report Market trend • Increase in strategic alliance and M&A • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2020 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? For more information or any query mail at sales@wiseguyreports.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com


News Article | November 30, 2016
Site: www.newsmaker.com.au

This analyst forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020.Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. The following companies are the key players in the global travel vaccines market: GlaxoSmithKline, Merck, Pfizer, and Sanofi. Other Prominent Vendors in the market are: Abbott, AstraZeneca, Bavarian Nordic, Baxter, Beijing Minhai Biotechnology, Bharat Biotech, Bharat Immunologicals and Biologicals, Bio-Med, Seqirus CSL, Crucell, CSL, Dynavax Technologies, Emergent BioSolutions, GlycoVaxyn, GreenSignal Bio Pharma, Hualan Biological Engineering, Imunoloski Zavod, Indian Immunologicals, Janssen Pharmaceuticals, JN International Medical, Kaketsuken, LG Life Sciences, Lupin, Mitsubishi Tanabe Pharma, Novavax, Nuron Biotech, Panacea Biotec, Pfizer, Protein Sciences, Roche, SK Chemicals, Serum Institute of India, Shenzhen Kangtai Biological Products, Sinovac Biotech, Takeda Pharmaceutical, Vacunas Finlay, Valeant Pharmaceuticals, Valneva, and Zydus Cadila. The market is divided into the following segments based on geography: Commenting on the report, an analyst said: "R&D is budding due to a strong need for new efficacious and better tolerated vaccines. The market presents huge growth potential for vendors because of the growing incidence of infectious disease. This requirement is creating a demand for novel vaccines where major players are focusing their R&D efforts and once launched, should become the major growth drivers. Increased investment in R&D by major pharmaceutical companies would fuel the growth of the global travel vaccines market." According to the report, the growing demand for vaccines among international travelers is one of the major factors driving the market growth. Many international and national bodies have mandated that the immigrants should be vaccinated before traveling to disease-prone areas. Considering vaccines are largely perceived as a prevention mechanism against the spread of any infectious disease; it is making a specific requirement in international traveler's list.


News Article | December 2, 2016
Site: www.prnewswire.co.uk

The global travel vaccines market analyst says R&D is budding due to a strong need for new efficacious and better tolerated vaccines. The market presents huge growth potential for vendors because of the growing incidence of infectious disease. This requirement is creating a demand for novel vaccines where major players are focusing their R&D efforts and once launched, should become the major growth drivers. Increased investment in R&D by major pharmaceutical companies would fuel the growth of the global travel vaccines market. Complete report on travel vaccines market spread across 60 pages, analysing 4 major companies and providing 64 data exhibits now available at http://www.reportsnreports.com/reports/769803-global-travel-vaccines-market-2016-2020.html. This analyst forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020. According to the travel vaccines market report, the growing demand for vaccines among international travellers is one of the major factors driving the market growth. Many international and national bodies have mandated that the immigrants should be vaccinated before traveling to disease-prone areas. Considering vaccines are largely perceived as a prevention mechanism against the spread of any infectious disease; it is making a specific requirement in international traveller's list. The Americas was the highest revenue contributing region in the travel vaccines market during 2015 and will continue to lead the market in the coming years. The US was one of the highest revenue contributors in the region, capturing a significant portion of the global market. The increasing demand for vaccines that cater to the unmet medical needs provides an opportunity for vendors to develop new safe and efficient molecules, which will aid in the growth of travel vaccines market in the region. The combination vaccines segment is one of the fastest growing segments of the travel vaccines market. These vaccines confer protection against different causative agents for diseases such as meningitis, measles, rubella, mumps, diphtheria, pertussis, and tetanus. The following companies are the key players in the global travel vaccines market: GlaxoSmithKline, Merck, Pfizer, and Sanofi. Other prominent vendors in the market are: Abbott, AstraZeneca, Bavarian Nordic, Baxter, Beijing Minhai Biotechnology, Bharat Biotech, Bharat Immunologicals and Biologicals, Bio-Med, Seqirus CSL, Crucell, CSL, Dynavax Technologies, Emergent BioSolutions, GlycoVaxyn, GreenSignal Bio Pharma, Hualan Biological Engineering, Imunoloski Zavod, Indian Immunologicals, Janssen Pharmaceuticals, JN International Medical, Kaketsuken, LG Life Sciences, Lupin, Mitsubishi Tanabe Pharma, Novavax, Nuron Biotech, Panacea Biotec, Pfizer, Protein Sciences, Roche, SK Chemicals, Serum Institute of India, Shenzhen Kangtai Biological Products, Sinovac Biotech, Takeda Pharmaceutical, Vacunas Finlay, Valeant Pharmaceuticals, Valneva, and Zydus Cadila. Order a copy of Global Travel Vaccines Market 2016-2020 report @ http://www.reportsnreports.com/purchase.aspx?name=769803. Global Travel Vaccines Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global travel vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of various vaccines administered to actively immunize meningococcal disease, Japanese encephalitis, rabies, typhoid, yellow fever, hepatitis B, and hepatitis A. The report also considers the revenues to be generated from the sales of vaccines that are expected to be launched into the market during the forecast period. Another related report is Global Human Vaccine Market 2016-2020, a major trend being witnessed in the global human vaccines market is the increase in strategic alliances. Increase in threat from regional vendors in developing countries may cause price erosion and may compel major players to operate under low-margin models. M&A are usually intended to increase the market penetration of the acquirer or to enhance the product portfolio of the parent company. Browse complete report @ http://www.reportsnreports.com/reports/461270-global-human-vaccine-market-2016-2020.html. Explore other new reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/. ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. Connect With Us on:

Loading Dynavax Technologies collaborators
Loading Dynavax Technologies collaborators